MET and lung cancer: Of 81 pulmonary SC, the frequency of MET exon 14 splice site mutations was 4.9%, i.e., the lowest rate yet reported, although this value is very close to the 7.7% rate recently reported by Schrock et al. for an American cohort of lung cancers including 104 SC analysed by a well-validated hybrid capture-based NGS [13].